TheDapa-SM
Triple Combination for Advanced Diabetes Management
Composition
Dapagliflozin 5mg, Sitagliptin 50mg & Metformin Hydrochloride 500mg Tablets
Description
TheDapa-SM is an innovative triple combination therapy that combines:
- Dapagliflozin: SGLT2 inhibitor that promotes glucose excretion
- Sitagliptin: DPP-4 inhibitor that enhances incretin effects
- Metformin: Improves insulin sensitivity and reduces glucose production
This unique combination provides comprehensive glycemic control through multiple complementary mechanisms.
Recommended Usage
Take as prescribed by your healthcare provider. Usually administered once daily with meals. Regular monitoring of blood glucose and kidney function is essential.
Product by Willkings Healthcare.
Key Benefits
- Triple-action mechanism for superior glycemic control
- Reduced risk of hypoglycemia
- Cardiovascular risk reduction
- Weight management support
- Once-daily convenient dosing